Corbus Pharmaceuticals Hldgs Inc (CRBP)

$7.47 -0.09 (-1.19%)
Market Cap 132.70M
Revenue (ttm) 0.00
Net Income (ttm) -40.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 69,098
Avg Vol 297,076
Day's Range N/A - N/A
Shares Out 17.55M
Stochastic %K 27%
Beta 2.86
Analysts Strong Sell
Price Target $42.33

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 963 0100
Fax: 617 663 6085
Address:
500 River Ridge Drive, Norwood, United States
RandomInvestor777
RandomInvestor777 Feb. 14 at 8:54 PM
$CRBP When's the expected readout for CRB-913? if completion is in summer?
1 · Reply
birdmine
birdmine Feb. 12 at 3:28 PM
$CRBP https://www.tradingview.com/news/globenewswire:d189cf833094b:0-corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference/ I wish this would actually mean movement, but we’ll have to wait and see.
0 · Reply
Estimize
Estimize Feb. 11 at 11:00 AM
Wall St is expecting -1.35 EPS for $CRBP Q1 [Reporting 05/12 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c
0 · Reply
Billyraybob
Billyraybob Feb. 10 at 11:46 PM
$CRBP This one is all about news releases!! hopefully good news!! when is the next news release on their pipeline drugs?
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 9:05 PM
$CRBP Current Stock Price: $7.89 Contracts to trade: $7.5 CRBP Feb 20 2026 Call Entry: $0.72 Exit: $1.41 ROI: 95% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
birdmine
birdmine Feb. 10 at 2:49 PM
$CRBP I would kill to hear any news from this place!!
0 · Reply
birdmine
birdmine Feb. 6 at 3:54 PM
$CRBP https://www.tipranks.com/news/insider-trading/top-corbus-executives-quietly-trim-their-stakes-in-high-profile-biotech-insider-trading
0 · Reply
moosegoose
moosegoose Feb. 6 at 2:27 PM
$CRBP nice recovery from yesterday’s bloodbath
0 · Reply
birdmine
birdmine Feb. 5 at 1:21 PM
$CRBP 😶😑🥹🤮🤮🤮🤮🤮
0 · Reply
birdmine
birdmine Feb. 2 at 4:44 PM
$CRBP this shit stock!!! Praying for a miracle!!!
0 · Reply
Latest News on CRBP
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Feb 12, 2026, 8:00 AM EST - 5 days ago

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 3:15 PM EST - 4 weeks ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:30 AM EST - 6 weeks ago

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Dec 11, 2025, 4:42 PM EST - 2 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Dec 11, 2025, 7:00 AM EST - 2 months ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Dec 10, 2025, 4:01 PM EST - 2 months ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 3 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Nov 5, 2025, 11:42 AM EST - 3 months ago

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 31, 2025, 2:40 AM EDT - 3 months ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 30, 2025, 4:31 PM EDT - 3 months ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Oct 18, 2025, 3:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Sep 16, 2025, 8:00 AM EDT - 5 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 25, 2025, 8:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 24, 2025, 4:05 PM EDT - 8 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Jun 17, 2025, 3:42 PM EDT - 8 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 28, 2025, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 14, 2025, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Feb 11, 2025, 7:30 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Mar 6, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 28, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30, 2024, 7:13 AM EST - 2 years ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 2:17 PM EST - 2 years ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

RandomInvestor777
RandomInvestor777 Feb. 14 at 8:54 PM
$CRBP When's the expected readout for CRB-913? if completion is in summer?
1 · Reply
birdmine
birdmine Feb. 12 at 3:28 PM
$CRBP https://www.tradingview.com/news/globenewswire:d189cf833094b:0-corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference/ I wish this would actually mean movement, but we’ll have to wait and see.
0 · Reply
Estimize
Estimize Feb. 11 at 11:00 AM
Wall St is expecting -1.35 EPS for $CRBP Q1 [Reporting 05/12 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c
0 · Reply
Billyraybob
Billyraybob Feb. 10 at 11:46 PM
$CRBP This one is all about news releases!! hopefully good news!! when is the next news release on their pipeline drugs?
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 9:05 PM
$CRBP Current Stock Price: $7.89 Contracts to trade: $7.5 CRBP Feb 20 2026 Call Entry: $0.72 Exit: $1.41 ROI: 95% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
birdmine
birdmine Feb. 10 at 2:49 PM
$CRBP I would kill to hear any news from this place!!
0 · Reply
birdmine
birdmine Feb. 6 at 3:54 PM
$CRBP https://www.tipranks.com/news/insider-trading/top-corbus-executives-quietly-trim-their-stakes-in-high-profile-biotech-insider-trading
0 · Reply
moosegoose
moosegoose Feb. 6 at 2:27 PM
$CRBP nice recovery from yesterday’s bloodbath
0 · Reply
birdmine
birdmine Feb. 5 at 1:21 PM
$CRBP 😶😑🥹🤮🤮🤮🤮🤮
0 · Reply
birdmine
birdmine Feb. 2 at 4:44 PM
$CRBP this shit stock!!! Praying for a miracle!!!
0 · Reply
birdmine
birdmine Jan. 30 at 3:14 PM
$CRBP this company is driving me crazy!!!
0 · Reply
birdmine
birdmine Jan. 26 at 6:19 PM
$CRBP let it stick
0 · Reply
h8ster
h8ster Jan. 23 at 6:21 PM
$CRBP For the Russell to be down over 1.7% today is bonkers! Healthcare and finical taking it on the chin.
0 · Reply
birdmine
birdmine Jan. 22 at 3:15 PM
$CRBP 👀👀. Almost!!
0 · Reply
birdmine
birdmine Jan. 16 at 8:59 PM
$CRBP why won’t this get out of the 8 dollar range?!
0 · Reply
jeremy0916
jeremy0916 Jan. 16 at 6:51 PM
$CRBP $20+ after obesity data
1 · Reply
birdmine
birdmine Jan. 15 at 3:22 PM
$CRBP praying that this conference goes well!!
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jan. 15 at 1:56 PM
$CRBP Starter
1 · Reply
birdmine
birdmine Jan. 14 at 3:30 PM
$CRBP I hope the investors meeting tomorrow help drive the price up!!
1 · Reply
shlomiko
shlomiko Jan. 14 at 1:38 PM
$CRBP
0 · Reply
birdmine
birdmine Jan. 14 at 1:20 PM
$CRBP lame ass stock!! Lord, let this trash rise for once!!!
0 · Reply
moosegoose
moosegoose Jan. 13 at 7:55 PM
$CRBP
0 · Reply